peptide-therapy
Most coverage treats peptide regulation as one story. The reality is bifurcated: GLP-1 copycat compounding is being crushed, while 14 other peptides are being reviewed for restored legal access.
MOTS-c
MOTS-c is the only peptide with two human trials. One proved it worked — then the company dissolved. The second is running. July 23, the FDA decides compounding access.
obesity pharmacotherapy
A new amylin analogue (petrelintide) posted Phase 1 results: 8.6% body weight reduction at 16 weeks, nausea rate identical to placebo. Here's what that means for GLP-1 dropouts.
MOTS-c
A 16-amino-acid peptide encoded by mitochondrial DNA is generating compelling early metabolic data.
Alpha-Gal
The SAAT protocol offers a targeted approach for Alpha-Gal syndrome — a tick-borne allergy to red meat that's spreading across the country.
wearable technology
Continuous glucose monitors changed the game. Next-gen wearable IR sensors could monitor metabolic health in real-time, revealing what blood tests miss.
News
This is Leangevity, a brand new site by John Hawkins that's just getting started. Things will be up and running here shortly, but you can subscribe in the meantime if you'd like to stay up to date and receive emails when new content is published!